• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    October 29, 2024 - FDA Roundup: October 29, 2024

    10/29/24 3:30:19 PM ET
    $HOLX
    Medical Electronics
    Health Care
    Get the next $HOLX alert in real time by email
    For Immediate Release:
    October 29, 2024

    Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: 

    • Today, the FDA responded to objections on the agency’s final rule that removed the authorized food contact uses of most phthalates because industry abandoned these uses. The FDA evaluated the objections and concluded that they did not provide a basis for modifying the final rule. However, the FDA is working on an updated safety assessment of the remaining authorized uses, including considering information we have received through our request for information, and phthalates are included on the list of select chemicals under FDA review.
    • On Monday, the FDA announced a hybrid meeting, In Vitro Diagnostics (IVD) Roundtable, that will be held on Nov. 12, 2024, at 10 a.m. ET. The meeting will provide a forum to facilitate communication between the FDA and IVD industry. Participants can attend in-person or virtually. Space is limited for in-person attendance. There is no fee to attend, and registration is required. To attend in person, register by Oct. 30, 2024. To attend virtually, register by Nov. 12, 2024.
    • On Monday, the FDA shared information about medical device cybersecurity. Like other electronics, medical devices can be vulnerable to security breaches, potentially impacting the safety and effectiveness of the device. Informed by patient voices and collaborations with industry, government agencies, and health care delivery organizations, the FDA will continue to drive and refine medical device cybersecurity policy. Before Cybersecurity Awareness Month ends, check out these recent publications that may be generally informative to help keep medical devices operating safely.
    • On Friday, the FDA issued a safety communication to alert consumers, health care providers, and health care facilities not to use BioZorb Markers and BioZorb LP Markers by Hologic Inc. On Oct. 25, 2024, Hologic announced a voluntary recall for removal of all lots of unused BioZorb Markers. The recall is due to reports of serious adverse events occurring in patients who had the devices implanted in breast tissue. 
    • On Friday, the FDA granted marketing authorization of Distalmotion, SA’s Dexter L6 System, an electromechanical surgical system intended to repair inguinal hernias through minimally invasive procedures using high-precision surgical endoscopic instruments. The Dexter L6 System includes a console surgeons use to control movements of the different parts of the system, separate carts that can be positioned next to the operating room table, and arms that get attached to the carts and that can hold and manipulate different endoscopic instruments based on motions captured on the surgeon-controlled console. Although the Dexter L6 Surgical System operates using similar principles as other robotically assisted surgery device systems, it allows for the surgeon and the user interface to be in the sterile field, unlike other authorized devices. The Dexter L6 System is intended for use by trained laparoscopic surgeons on patients 22 years of age or older. This authorization reinforces the FDA’s commitment to providing physicians and patients with minimally invasive surgery options to treat relatively common conditions, such as inguinal hernias.
    • On Friday, three individuals in London were sentenced for their role in the international importation and distribution of unapproved drugs. The operation seized over £1M ($1.3M) and 1 million illicit pills. This result is the culmination of numerous law enforcement agencies, including the FDA Office of Criminal Investigations (FDA-OCI), working together from across the world for more than three years. The investigation began in October 2020 when U.S. Customs and Border Protection seized numerous shipments sent from the U.K. found to contain illicit drugs. Information sharing between FDA-OCI and the City of London Police led to the successful execution of warrants in the U.S., where illicit unapproved drugs were found.

    Related Information

    Related Information
    • FDA Newsroom

    ###

    Boilerplate

    The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products.


    Inquiries

    Media:
    FDA Office of Media Affairs
    888-INFO-FDA
    Consumer:
    888-INFO-FDA

    Get the next $HOLX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HOLX

    DatePrice TargetRatingAnalyst
    1/12/2026Buy → Hold
    Argus
    1/5/2026$78.00Outperform → In-line
    Evercore ISI
    11/21/2025$79.00Outperform → Neutral
    BNP Paribas Exane
    10/7/2025$78.00In-line → Outperform
    Evercore ISI
    8/18/2025$80.00Hold → Buy
    Argus
    8/6/2025$87.00Sector Perform → Outperform
    RBC Capital Mkts
    7/9/2025$80.00Neutral → Buy
    Citigroup
    5/27/2025Hold
    Needham
    More analyst ratings

    $HOLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Hologic downgraded by Argus

    Argus downgraded Hologic from Buy to Hold

    1/12/26 9:02:06 AM ET
    $HOLX
    Medical Electronics
    Health Care

    Hologic downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded Hologic from Outperform to In-line and set a new price target of $78.00

    1/5/26 8:48:38 AM ET
    $HOLX
    Medical Electronics
    Health Care

    Hologic downgraded by BNP Paribas Exane with a new price target

    BNP Paribas Exane downgraded Hologic from Outperform to Neutral and set a new price target of $79.00

    11/21/25 8:06:35 AM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 29, 2024 - FDA Roundup: October 29, 2024

    For Immediate Release: October 29, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA responded to objections on the agency’s final rule that removed the authorized food contact uses of most phthalates because industry abandoned these uses. The FDA evaluated the objections and concluded that they did not provide a basis for mod

    10/29/24 3:30:19 PM ET
    $HOLX
    Medical Electronics
    Health Care

    February 2, 2024 - FDA Roundup: February 2, 2024

    For Immediate Release: February 02, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a safety communication to warn consumers, health care providers, and health care facilities not to use certain Cardinal Health Monoject luer-lock and enteral syringes. Dimensional changes made to the syringes, when used with syringe pump

    2/2/24 3:58:21 PM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Blackstone and TPG Complete Acquisition of Hologic

    Accomplished MedTech leader Joe Almeida named Chief Executive Officer Hologic, Inc. (NASDAQ:HOLX), a global leader in women's health, today announced the completion of its acquisition by funds managed by Blackstone and TPG in a transaction valued at up to $79 per share, establishing Hologic as a private company. The transaction includes significant minority investments from a wholly owned subsidiary of the Abu Dhabi Investment Authority ("ADIA") and an affiliate of GIC. In connection with the completion of this transaction, Hologic today announced the appointment of José (Joe) E. Almeida as Chief Executive Officer, effective immediately. "Hologic is an incredible company with a storied

    4/7/26 9:10:00 AM ET
    $HOLX
    Medical Electronics
    Health Care

    Casey's General Stores Set to Join S&P 500; DigitalOcean Holdings to Join S&P MidCap 400; Broadstone Net Lease to Join S&P SmallCap 600

    NEW YORK, April 6, 2026 /PRNewswire/ -- S&P MidCap 400 constituent Casey's General Stores Inc. (NASD: CASY) will replace Hologic Inc. (NASD: HOLX) in the S&P 500, S&P SmallCap 600 constituent DigitalOcean Holdings Inc. (NYSE:DOCN) will replace Casey's General Stores in the S&P MidCap 400, and Broadstone Net Lease Inc. (NYSE:BNL) will replace DigitalOcean Holdings in the S&P SmallCap 600 effective prior to the opening of trading on Thursday, April 9. Affiliates of Blackstone Inc. and TPG Global are acquiring Hologic in a deal expected to be completed on or about April 7. Following is a summary of the changes that will take place prior to the open of trading on the effective date:Effective Dat

    4/6/26 5:51:00 PM ET
    $BNL
    $CASY
    $DOCN
    Real Estate Investment Trusts
    Real Estate
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    Hologic Chief Executive Officer Steve MacMillan to Retire Upon Close of Go-Private Transaction

    Hologic, Inc. (NASDAQ:HOLX) announced today that Steve MacMillan, its long-time Chairman, President and Chief Executive Officer (CEO), has decided to retire when the Company's go-private transaction with Blackstone and TPG closes. All required regulatory approvals have now been received for the transaction, which is expected to close on or about April 7, 2026. "Hologic's board of directors, and all the Company's stakeholders, owe a debt of gratitude to Steve, one of the most respected leaders in the medical technology industry," said Amy Wendell, Hologic's lead independent director. "He forged a dramatic turnaround shortly after joining the Company, led us through years of consistent gr

    4/6/26 8:00:00 AM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $HOLX
    SEC Filings

    View All

    $HOLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    General Counsel Liddy Anne M. covered exercise/tax liability with 185 shares, decreasing direct ownership by 0.66% to 28,052 units (SEC Form 4)

    4 - HOLOGIC INC (0000859737) (Issuer)

    3/2/26 4:30:37 PM ET
    $HOLX
    Medical Electronics
    Health Care

    Director Wendell Amy Mcbride was granted 3,190 shares, increasing direct ownership by 14% to 25,784 units (SEC Form 4)

    4 - HOLOGIC INC (0000859737) (Issuer)

    3/2/26 4:29:04 PM ET
    $HOLX
    Medical Electronics
    Health Care

    Director Stewart Stacey D. was granted 3,190 shares, increasing direct ownership by 62% to 8,358 units (SEC Form 4)

    4 - HOLOGIC INC (0000859737) (Issuer)

    3/2/26 4:27:37 PM ET
    $HOLX
    Medical Electronics
    Health Care

    Hologic Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure

    8-K - HOLOGIC INC (0000859737) (Filer)

    4/7/26 9:17:42 AM ET
    $HOLX
    Medical Electronics
    Health Care

    Hologic Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - HOLOGIC INC (0000859737) (Filer)

    4/6/26 8:00:56 AM ET
    $HOLX
    Medical Electronics
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Hologic Inc.

    SCHEDULE 13G/A - HOLOGIC INC (0000859737) (Subject)

    3/27/26 9:33:26 AM ET
    $HOLX
    Medical Electronics
    Health Care

    Director Madaus Martin D bought $300,760 worth of shares (5,445 units at $55.24) (SEC Form 4)

    4 - HOLOGIC INC (0000859737) (Issuer)

    5/9/25 4:39:33 PM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    Leadership Updates

    Live Leadership Updates

    View All

    Blackstone and TPG Complete Acquisition of Hologic

    Accomplished MedTech leader Joe Almeida named Chief Executive Officer Hologic, Inc. (NASDAQ:HOLX), a global leader in women's health, today announced the completion of its acquisition by funds managed by Blackstone and TPG in a transaction valued at up to $79 per share, establishing Hologic as a private company. The transaction includes significant minority investments from a wholly owned subsidiary of the Abu Dhabi Investment Authority ("ADIA") and an affiliate of GIC. In connection with the completion of this transaction, Hologic today announced the appointment of José (Joe) E. Almeida as Chief Executive Officer, effective immediately. "Hologic is an incredible company with a storied

    4/7/26 9:10:00 AM ET
    $HOLX
    Medical Electronics
    Health Care

    Casey's General Stores Set to Join S&P 500; DigitalOcean Holdings to Join S&P MidCap 400; Broadstone Net Lease to Join S&P SmallCap 600

    NEW YORK, April 6, 2026 /PRNewswire/ -- S&P MidCap 400 constituent Casey's General Stores Inc. (NASD: CASY) will replace Hologic Inc. (NASD: HOLX) in the S&P 500, S&P SmallCap 600 constituent DigitalOcean Holdings Inc. (NYSE:DOCN) will replace Casey's General Stores in the S&P MidCap 400, and Broadstone Net Lease Inc. (NYSE:BNL) will replace DigitalOcean Holdings in the S&P SmallCap 600 effective prior to the opening of trading on Thursday, April 9. Affiliates of Blackstone Inc. and TPG Global are acquiring Hologic in a deal expected to be completed on or about April 7. Following is a summary of the changes that will take place prior to the open of trading on the effective date:Effective Dat

    4/6/26 5:51:00 PM ET
    $BNL
    $CASY
    $DOCN
    Real Estate Investment Trusts
    Real Estate
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    Biote Announces CEO Retirement and Succession Plan

    Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company's Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Director biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company's Board of Directors, effective as of February 1, 2025. She will be transitioning to Strategic Advisor to the Company's Board of Directors. Concurrently, Mr. Bret Christensen has been named Chief Executi

    1/30/25 4:10:00 PM ET
    $BTMD
    $HOLX
    $MYGN
    Medicinal Chemicals and Botanical Products
    Health Care
    Medical Electronics
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    $HOLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Hologic Inc.

    SC 13G/A - HOLOGIC INC (0000859737) (Subject)

    11/14/24 1:28:29 PM ET
    $HOLX
    Medical Electronics
    Health Care

    SEC Form SC 13G filed by Hologic Inc.

    SC 13G - HOLOGIC INC (0000859737) (Subject)

    2/14/24 10:04:34 AM ET
    $HOLX
    Medical Electronics
    Health Care

    SEC Form SC 13G/A filed by Hologic Inc. (Amendment)

    SC 13G/A - HOLOGIC INC (0000859737) (Subject)

    2/9/23 11:22:19 AM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    Financials

    Live finance-specific insights

    View All

    Hologic Announces Financial Results for First Quarter of Fiscal 2026

    – Revenue of $1,047.8 Million Grows 2.5% – – GAAP Diluted EPS of $0.79 Decreases (9.2%), Non-GAAP Diluted EPS of $1.04 Up 1.0% – Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal first quarter ended December 27, 2025. The Company reported revenue of $1,047.8 million, GAAP diluted EPS of $0.79, and non-GAAP diluted EPS of $1.04. Highlights The Company has scheduled for February 5, 2026 a special meeting of stockholders to vote on adopting the merger agreement with funds managed by Blackstone and TPG, and related matters. Revenue of $1,047.8 million increased 2.5% for the quarter, or 1.3% on a constant currency basis. Total organic reve

    1/29/26 4:02:00 PM ET
    $HOLX
    Medical Electronics
    Health Care

    Hologic to Announce Financial Results for the First Quarter of Fiscal 2026 on Thursday, January 29, 2026

    Hologic, Inc. (NASDAQ:HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2026 on Thursday, January 29, after the market closes. As previously announced, in light of Hologic's pending acquisition by Blackstone and TPG, the Company will not be hosting a quarterly conference call or providing financial guidance. About Hologic Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com. SOURCE: Hologic, Inc. View source version on businesswire.com: https://www.businesswire.com/

    1/15/26 7:00:00 PM ET
    $HOLX
    Medical Electronics
    Health Care

    Hologic Announces Financial Results for Fourth Quarter of Fiscal 2025

    – Revenue of $1,049.5 Million Grows 6.2% – – GAAP Diluted EPS of $0.83 Increases 9.2%, Non-GAAP Diluted EPS of $1.13 Up 11.9% – Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal fourth quarter ended September 27, 2025. The Company reported revenue of $1,049.5 million, GAAP diluted EPS of $0.83, and non-GAAP diluted EPS of $1.13. Highlights On October 21, 2025, the Company announced it had entered into a definitive agreement to be acquired by funds managed by Blackstone and TPG in a transaction valued at up to $79 per share (the "Proposed Transaction"). Revenue of $1,049.5 million increased 6.2% for the quarter, or 5.4% in constant currenc

    11/3/25 4:01:00 PM ET
    $HOLX
    Medical Electronics
    Health Care